LymeSpot Revised: The new generation EliSpot | April 17, 2015
EliSpot is used to detect an infection of Borrelia and its co-infections on a cellular level. It is trustworthy and we have now been using it for several years. The first generation of enzymatic EliSpots determined the interferon-gamma production of cells and provided vital information about the infection. We have now developed this test even further.
The new EliSpot, ‘LymeSpot Revised’, delivers detailed information about the activity of the infection and/or inflammation. This test can better differentiate between an active (specific effector-cells) or latent (specific memory-cells) infection. As a result, it is now possible to evaluate whether it is an infection, inflammation or autoimmune processes that are prevailing. In comparison with EliSpot, which is based on the production of interferon-γ, LymeSpot also determines the levels of cytokine IL-2.
For more information, click here
On the 12th of February 2015, a new study was published that demonstrates the clinical benefits of the therapeutic approach by EliSpot Assay in identifying the two cytokines Gamma-Interferon and Interleukin-2 amongst patients with acute and chronic Q-fever. Q-fever is also a tick-borne disease. You can find this study here.